U.S. pharma big copyright scrapped two experimental weight loss products past year—a at the time-each day pill, lotiglipron, as a consequence of elevated liver enzymes as well as a 2 times-every day capsule, danuglipron, because of robust Unintended effects—but CEO Albert Bourla has explained the company is set to “Participate in and gain”